Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,931,222
  • Shares Outstanding, K 342,833
  • Annual Sales, $ 7,870 K
  • Annual Income, $ -567,940 K
  • EBIT $ -233 M
  • EBITDA $ -232 M
  • 60-Month Beta 1.58
  • Price/Sales 361.86
  • Price/Cash Flow N/A
  • Price/Book 8.74

Options Overview Details

View History
  • Implied Volatility 85.74% (-4.03%)
  • Historical Volatility 131.19%
  • IV Percentile 7%
  • IV Rank 3.47%
  • IV High 585.10% on 04/08/25
  • IV Low 67.79% on 07/22/25
  • Expected Move (DTE 13) 1.22 (14.22%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 1,719
  • Volume Avg (30-Day) 3,460
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 67,387
  • Open Int (30-Day) 70,667
  • Expected Range 7.33 to 9.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 4
  • High Estimate -0.08
  • Low Estimate -0.15
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.45 +92.13%
on 11/07/25
8.70 -1.72%
on 12/05/25
+3.63 (+73.78%)
since 11/05/25
3-Month
2.99 +185.95%
on 09/25/25
8.70 -1.72%
on 12/05/25
+4.65 (+119.23%)
since 09/05/25
52-Week
1.54 +455.19%
on 04/07/25
8.70 -1.72%
on 12/05/25
+5.78 (+208.66%)
since 12/05/24

Most Recent Stories

More News
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions...

NUVB : 8.55 (+2.89%)
Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive...

NUVB : 8.55 (+2.89%)
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Successfully started 204 patients on IBTROZI ™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI’s unprecedented durability...

NUVB : 8.55 (+2.89%)
Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive...

NUVB : 8.55 (+2.89%)
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

No targeted treatments are currently FDA approved for high-grade IDH1 -mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203...

NUVB : 8.55 (+2.89%)
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday,...

NUVB : 8.55 (+2.89%)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Nuvation Bio (NUVB) and QT Imaging Holdings (OtherQTIH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research Report), Nuvation Bio (NUVB – Research Report) and QT Imaging Holdings...

CGEM : 10.59 (+0.09%)
QTIH : 6.1400 (-0.45%)
NUVB : 8.55 (+2.89%)
Nuvation Bio (NUVB) Receives a Buy from RBC Capital

In a report released on October 8, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio. The company’s shares closed yesterday at $3.75.Elevate Your Investing Strategy: Take advantage...

NUVB : 8.55 (+2.89%)
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Trial initiation follows the recent approval of IBTROZI™ (taletrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer

NUVB : 8.55 (+2.89%)
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

IBTROZI will be marketed in Japan by Nippon Kayaku Approval is based on the pivotal Phase 2 TRUST studies, demonstrating IBTROZI's high rates and durability of responses...

NUVB : 8.55 (+2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 9.33
2nd Resistance Point 9.02
1st Resistance Point 8.78
Last Price 8.55
1st Support Level 8.23
2nd Support Level 7.92
3rd Support Level 7.68

See More

52-Week High 8.70
Last Price 8.55
Fibonacci 61.8% 5.96
Fibonacci 50% 5.12
Fibonacci 38.2% 4.28
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar